AAD: Low Rate of Hyperkalemia With Spironolactone Use
(HealthDay News) — Healthy immature women holding spironolactone for acne have no increasing rate of hyperkalemia, according to a investigate published online Mar 22 in JAMA Dermatology to coincide with a annual assembly of a American Academy of Dermatology, hold from Mar 20 to 24 in San Francisco.
Molly Plovanich, M.D., from Brigham and Women’s Hospital in Boston, and colleagues totalled a rate of hyperkalemia in healthy immature women holding spironolactone for acne or an endocrine commotion with compared acne. Data were enclosed for 974 healthy immature women holding spironolactone for acne. To obtain a form for a baseline rate of hyperkalemia in this population, a authors analyzed 1,165 healthy immature women holding and not holding spironolactone.
The researchers identified 13 aberrant serum potassium measurements in 1,802 measurements, agreeable a hyperkalemia rate of 0.72 percent among immature women receiving spironolactone therapy. This was homogeneous to a baseline hyperkalemia rate of 0.76 percent in this population. In 6 of a 13 patients, repeat contrast demonstrated normal values, indicating a measurements might have been incorrect. No movement was taken in a remaining 7 patients.
“In conclusion, a formula advise that slight potassium monitoring is nonessential for healthy immature women holding spironolactone for acne,” a authors write. “The low rate of hyperkalemia might inspire some-more health caring professionals to cruise a use of this rarely effective drug in their clinical practice.”